Santos-Valente, Elisangela and Buntrock-Dopke, Heike and Abou Taam, Rola and Arasi, Stefania and Bakirtas, Arzu and Lozano Blasco, Jaime and Bonnelykke, Klaus and Craiu, Mihai and Cutrera, Renato and Deschildre, Antoine and Elnazir, Basil and Fleming, Louise and Frey, Urs and Gappa, Monika and Nieto Garcia, Antonio and Hansen, Kirsten Skamstrup and Hanssens, Laurence and Jahnz-Rozyk, Karina and Jesenak, Milos and Kerzel, Sebastian and Kopp, Matthias and Koppelman, Gerard H. and Krivec, Uros and MacLeod, Kenneth A. and Makela, Mika and Melen, Erik and Mezei, Gyorgyi and Moeller, Alexander and Moreira, Andre and Pohunek, Petr and Minic, Predrag and Rutjes, Niels W. P. and Sammut, Patrick and Schwerk, Nicolaus and Szepfalusi, Zsolt and Turkalj, Mirjana and Tzotcheva, Iren and Ulmeanu, Alexandru and Verhulst, Stijn and Xepapadaki, Paraskevi and Niggel, Jakob and Vijverberg, Susanne and Maitland-van der Zee, Anke H. and Potocnik, Uros and Reinartz, Susanne M. and van Drunen, Cornelis M. and Kabesch, Michael (2021) Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo. ERJ OPEN RESEARCH, 7 (3): 00143-2021. ISSN , 2312-0541
Full text not available from this repository. (Request a copy)Abstract
Introduction Severe asthma is a rare disease in children, for which three biologicals, anti-immunoglobulin E, anti-interleukin-5 and anti-IL4RA antibodies, are available in European countries. While global guidelines exist on who should receive biologicals, knowledge is lacking on how those guidelines are implemented in real life and which unmet needs exist in the field. In this survey, we aimed to investigate the status quo and identify open questions in biological therapy of childhood asthma across Europe. Methods Structured interviews regarding experience with biologicals, regulations on access to the different treatment options, drug selection, therapy success and discontinuation of therapy were performed. Content analysis was used to analyse data. Results We interviewed 37 experts from 25 European countries and Turkey and found a considerable range in the number of children treated with biologicals per centre. All participating countries provide public access to at least one biological. Most countries allow different medical disciplines to prescribe biologicals to children with asthma, and only a few restrict therapy to specialised centres. We observed significant variation in the time point at which treatment success is assessed, in therapy duration and in the success rate of discontinuation. Most participating centres intend to apply a personalised medicine approach in the future to match patients a priori to available biologicals. Conclusion Substantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Kinder- und Jugendmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 21 Sep 2022 07:16 |
| Last Modified: | 21 Sep 2022 07:16 |
| URI: | https://pred.uni-regensburg.de/id/eprint/47778 |
Actions (login required)
 |
View Item |
